Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer

Annals of Internal Medicine

Volumn 129, Issue 12, 1998, Pages 1027-1030

  Furuta, Takahisa ^a   Ohashi, Kyoichi ^a   Kamata, Takashi ^b   Takashima, Misako ^a   Kosuge, Kazuhiro ^a   Kawasaki, Tsunehisa ^a   Hanai, Hiroyuki ^a   Kubota, Takahiro ^c   Ishizaki, Takashi ^d   Kaneko, Eizo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Honda Motor   (Japan)

^c SRL INC   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4' HYDROXYMEPHENYTOIN; AMOXICILLIN; HYDROLASE; OMEPRAZOLE;

ADULT; ARTICLE; DRUG EFFICACY; DRUG METABOLISM; DUODENUM ULCER; FEMALE; GENOTYPE; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; STOMACH ULCER;

EID: 0000140377     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-12-199812150-00006     Document Type: Article

References (20)

1. Goodwin CS, Mendall MM, Northfield TC. Helicobacter pylori infection. Lancet. 1997;349:265-9.
2. Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA. 1996;275:622-9.
3. Ofman JJ, Etchason J, Fullerton S, Kahn KL, Soll AH. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med. 1997;126:280-91.
4. al-Assi MT, Cole RA, Karttunen TJ, el-Zimaity H, Genta RM, Graham DY. Treatment of Helicobacter pylori infection with omeprazole-amoxicillin combination therapy versus ranitidine/sodium bicarbonate-amoxicillin. Am J Gastroenterol. 1995;90:1411-4.
5. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer diseases. N Engl J Med. 1995;333:984-91.
6. Unge P. Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol. 1996;31(Suppl 215):74-81.
7. Cederbrant G, Kahlmeter G, Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother. 1992;29: 115-20.
8. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 1992;11:777-81.
9. Peterson WL, Graham DY, Marshall B, Blaser MJ, Genta RM, Klein PD, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol. 1993;88:1860-4.
10. Sohn DR. Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther. 1992;262:1195-202.
11. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol. 1995;39:511-8.
12. Ieiri I, Kubota T, Urae A. Kimura M, Wada Y, Mamiya K, et al. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther. 1996;59:647-53.
13. Furuta T, Kaneko E, Suzuki M, Arai H, Futami H. Quantitative study of Helicobacter pylori in gastric mucus by competitive PCR using synthetic DNA fragments. J Clin Microbiol. 1996;34:2421-5.
14. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419-22.
15. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594-8.
16. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther. 1996;60: 661-6.
17. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC Jr. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1989;8:888-9.
18. Goddard AF, Jessa MJ, Barren DA, Shaw PN, Idstrom JP, Cederberg C, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology. 1996;111:358-67.
19. Midolo PD, Turnidge JD, Lambert JR, Bell JM. Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro. Antimicrob Agents Chemother. 1996;40:1531-3.
20. Bayerdorffer E, Miehlke S, Mannes GA, Sommer A, Hochter W, Weingart J, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology. 1995;108:1412-7.